| Assessment Status |
Assessment Process Complete |
| HTA ID |
- |
| Drug |
Mannitol Dry Powder |
| Brand |
Bronchitol® |
| Indication |
Mannitol dry powder for inhalation for the treatment of cystic fibrosis (CF) |
| Rapid review commissioned |
11/09/2012 |
| Rapid review completed |
21/09/2012 |
| Rapid review outcome |
Full Pharmacoeconomic Evaluation Recommended |
| Full submission received from Applicant |
14/03/2014 |
| NCPE assessment completed |
29/08/2014 |
| NCPE assessment outcome |
Reimbursement not recommended |
Technical Summary 2014
| Assessment Status |
Rapid Review Complete |
| Rapid review received |
02/04/2019 |
| Rapid review completed |
29/04/2019 |
| Rapid review outcome |
A full HTA is not recommended. The NCPE recommends that Mannitol Dry Powder (Bronchitol®) not be considered for reimbursement. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
